We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Magnetic Resonance Imaging (MRI) of Brain Iron in Neurodegenerative Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00249080
First Posted: November 7, 2005
Last Update Posted: August 24, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
United States Department of Defense
Information provided by:
Albany Medical College
November 3, 2005
November 7, 2005
August 24, 2009
June 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00249080 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Magnetic Resonance Imaging (MRI) of Brain Iron in Neurodegenerative Disease
High Field MRI of Brain Iron in Neurodegenerative Disease
Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis are recognized as a major health concern at the present time. There is information in magnetic resonance imaging (MRI) studies regarding the role of brain iron in normal brain aging that may be enhanced with the use of better scanning equipment and procedures, and by correlating this information with clinical data. This research study aims to develop and evaluate a number of techniques that can potentially improve the effectiveness of three tesla (3T) magnetic resonance imaging of neurodegenerative brain disorders.

Eligibility: A healthy person without memory complaints or someone with neurodegenerative disease. However, the person should not have metal in the body (ie, pacemaker, implants, shrapnel, etc.), should not be pregnant, and should not have claustrophobic anxieties.

Study Procedures: During a regular office visit, a neurologist will perform a routine physical and neurological examination, including your medical and family history, to determine your eligibility for this study. You will then be scheduled for a series of neuropsychological tests, which take between 1 to 1.5 hours, and an MRI scan, which takes approximately 1 hour to complete. This is a longitudinal study and you may be asked to repeat these procedures approximately every six months for the duration of this 2 year project.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Approximately equal numbers of subjects with clinically diagnosed Alzheimer's disease, multiple sclerosis, Parkinson's disease and normal controls (age and gender matched).
  • Neurodegenerative Diseases
  • Mild Cognitive Impairment
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
182
August 2007
Not Provided

Inclusion Criteria:

  • 18 years or older
  • Healthy person without memory complaints OR person diagnosed with a neurodegenerative disease (ie, Alzheimer's disease, Parkinson's disease, multiple sclerosis)

Exclusion Criteria:

  • MR contraindication such as metal in body (ie, pacemaker, implant, shrapnel, etc.)
  • Pregnant
  • Claustrophobic anxieties
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00249080
AMC-IRB-1599
A-13214
Yes
Not Provided
Not Provided
John Schenck, MD PhD; Principal Investigator, Albany Medical College
Albany Medical College
United States Department of Defense
Study Director: Earl A Zimmerman, MD Albany Medical College
Principal Investigator: John F Schenck, MD, PhD GE Global Research Center & Neurosciences Advanced Imaging Research Center
Albany Medical College
August 2009